Form 4: Director Acquires CLDI Shares & Warrants in Public Offering

Calidi Biotherapeutics Director James A. Schoeneck purchased 75,000 common shares and warrants in a public offering on August 21, 2025, for $2.00 per unit.

Summary

• Director James A. Schoeneck acquired 75,000 shares of Calidi Biotherapeutics, Inc. common stock.
• He also acquired 75,000 warrants, each accompanying a common share, as part of the same transaction.
• The acquisition occurred on August 21, 2025, through a public offering conducted by the Issuer.
• The purchase price for each common share and accompanying warrant was $2.00.
• Following this transaction, Schoeneck directly owns 75,000 common shares and 75,000 warrants.
• He also indirectly owns 347 common shares with his spouse and 8,033 common shares through the James & Cynthia Schoeneck Family Trust.

Sentiment

Score: 7

Explanation: The director's purchase of shares and warrants in a public offering suggests confidence in the company's future, which is generally viewed positively by the market. However, this is a routine insider transaction disclosure rather than a significant operational or financial update.

Positives

• Director James A. Schoeneck increased his direct beneficial ownership in Calidi Biotherapeutics by acquiring 75,000 common shares and 75,000 warrants, signaling confidence in the company's future.
• Insider buying, particularly by a director, can be interpreted as a positive indicator of management's belief in the company's valuation and prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal of management confidence, potentially influencing market sentiment.
• The public offering, of which this transaction is a part, contributes to the company's capital base, which could support future operations and strategic initiatives.

Key Dates

Recommendation

While the director's purchase of shares and warrants indicates confidence in Calidi Biotherapeutics, a Form 4 filing primarily discloses insider transactions and does not provide sufficient financial or strategic details to warrant a 'buy' or 'sell' recommendation. It serves as a positive signal, suggesting a 'hold' position while awaiting more comprehensive financial disclosures.

Keywords

Calidi Biotherapeutics, CLDI, Form 4, Insider Trading, Beneficial Ownership, Director Purchase, Public Offering, Warrants, Biotherapeutics